PER® Congress on Hematologic Malignancies (Winter Hematology®) | Conference

Dr. Sotomayor on Precision Medicine for the Prevention of Cancer

February 23rd 2015

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses the future of personalized medicine in lymphoma.

Molecular Analysis Should Guide Treatment Individualization in AML

February 23rd 2015

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment for patients of acute myeloid leukemia, according to a presentation by Stefan Faderl, MD, at the 2015 International Congress on Hematologic Malignancies.

Dr. Wierda on Frontline Therapy for Older CLL Patients Compared to Younger

February 23rd 2015

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses the different standard frontline therapies for patients with chronic lymphocytic leukemia.

New Approaches Emerge for Treating ALL, Yet Challenges Remain

February 23rd 2015

The treatment landscape for acute lymphoblastic leukemia (ALL) is changing, pointing to promising new approaches clinicians can use in practice.

Integration of Novel CLL Agents Into Frontline Setting Continues to Evolve

February 21st 2015

Jeffrey Jones, MD, presented evidence supporting the integration of obinutuzumab, ibrutinib, ofatumumab, and idelalisib into the frontline setting for patients with chronic lymphocytic leukemia.

Novel Therapies in Hodgkin Lymphoma Coming to Clinics

February 21st 2015

Although treatments and cure rates have increased significantly over the past 60 years for patients with Hodgkin lymphoma, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.

Chemotherapy for CLL Not Yet Obsolete But in Flux as New Agents Gain Ground

February 21st 2015

Standard chemotherapy remains part of the treatment paradigm for patients with chronic lymphocytic leukemia but its role is undergoing a major shift as significant advances are being made in novel therapies.

Dr. Shuo Ma on Non-Chemotherapy Regimens for Hematologic Malignancies

February 20th 2015

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

Treatment Triplets Offer New Strategies in Relapsed Multiple Myeloma

February 20th 2015

The treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens, according to Sundar Jagannath, MD.

Sequencing Therapies in Follicular Lymphoma Requires Multifaceted Approach

February 20th 2015

The indolent nature of follicular lymphoma and the range of treatment options currently available or in development may create complicated questions regarding how to best use and sequence these therapies.

Dr. Treon on Breakthroughs in WaldenstrÃ¶m's Macroglobulinemia

February 20th 2015

Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, discusses the game-changing discoveries in Waldenstrom's Macroglobulinemia that led to the approval of ibrutinib for treatment of the disease.

Dr. Sundar Jagannath Discusses Approval of Lenalidomide in Multiple Myeloma

February 20th 2015

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses the recent approval of lenalidomide as a therapy for patients with multiple myeloma.

Dr. Michael Mauro on Treatment Discontinuation for CML

February 20th 2015

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.

Immunotherapy, Personalized Medicine to Highlight Winter Hematology Meeting

February 20th 2015

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

Treatment Landscape for Mantle Cell Lymphoma Continues to Evolve

April 16th 2014

Lymphoma expert Andre Goy, MD, provides insight into the rapidly changing treatment landscape for patients with mantle cell lymphoma.

Dr. Brentjens on Challenges of CAR-Modified T Cells

March 31st 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Dr. Anas Younes Discusses IPI-145 and ABT-199

March 19th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the clinical value of IPI-145 and ABT-199 as treatment options for lymphoid malignancies.

Dr. Wierda on the Treatment of Elderly CLL Patients

March 12th 2014

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment recommendations for patients with CLL.

Dr. Erba on BCR-ABL Ratio After Imatinib in CML

February 25th 2014

Harry Erba, MD, PhD, discusses the frequency in which patients with chronic-phase chronic myeloid leukemia (CML) fail to achieve a BCR-ABL transcript level below 10% after 3 months of treatment with imatinib.

Dr. Litzow on MRD Assessment in ALL

February 19th 2014

Mark R. Litzow. MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses ways of conducting minimal residual disease (MRD) assessments in patients with acute lymphoblastic leukemia